panflu Stats

[Mixin]

Clinical Infectious Diseases April 2009;48:1087-1095

Generally, higher immune responses were elicited in participants vaccinated 28 days apart than those vaccinated 14 days apart.

Conclusions
The inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine not only showed good immunogenicity and safety but also elicited significant cross-reactivity against heterologous H5N1 strains in clade 2.

Background
Avian influenza A virus H5N1 has the potential to cause a pandemic. Adjuvants and whole-virion vaccines are regarded as antigen sparing for pandemic vaccines.

Methods
A double-blind, randomized trial was performed from 28 August to 22 December 2007 in 402 adults; 301 adults were randomly assigned to receive 2 doses of an inactivated, aluminum-adjuvanted, whole-virion H5N1 vaccine containing 5, 10, or 15 ug of hemagglutinin per dose 28 days apart, and 101 of them received 2 doses of 10 ug of vaccine 14 days apart. The vaccine was manufactured from the recombinant A/Vietman/1194/2004 (NIBRG14) strain. Blood samples were collected for hemagglutination inhibition and microneutralization assays.

Results
All formulations were well tolerated, with no serious adverse events. Most local and systemic reactions were mild or moderate. Immune responses were induced after 1 dose in all vaccination groups. The highest immune response was seen after 2 doses of 15 ug of vaccine, with 90% and 100% seroconversion rates and 90% and 100% of participants having a titer of 1:40 for hemagglutination inhibition and microneutralization assays, respectively. Both the 10 and 15 ug doses met or exceeded European Union licensure criteria.

Cross-reaction assays showed that after 2 doses of 10 ug of vaccine, 98% and 87% of participants had a microneutralization titer of 1:40 against heterologous Indonesia and Anhui strains, respectively.

Trial registration.ClinicalTrials.gov identifier: NCT00535665.
http://www.journals.uchicago.edu/doi/abs/10.1086/597401
_________________
https://twitter.com/mixin1771